Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5125701 | 0.98 | TDP1 (0.53) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL631719 | 0.90 | TDP1 (0.60) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL20801639 | 0.90 | TDP1 (0.60) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL9998912 | 0.90 | TDP1 (0.60) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL2084039 | 0.89 | MAOA (0.66) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3177182 | 0.89 | MAOA (0.61) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3341020 | 0.87 | TDP1 (0.67) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL14472344 | 0.87 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL10050115 | 0.86 | TDP1 (0.53) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL10050077 | 0.86 | TDP1 (0.53) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250019387-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION | 2025-01-16 | — | — | US | disclosed |
| US-20250002522-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2025-01-02 | — | — | US | disclosed |
| EP-4426695-A1 | KRAS G12C INHIBITORS | Frontier Medicines Corporation (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118414345-A | Oligosaccharide compounds and complexes | 生物技术公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118239953-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2024-06-25 | — | — | CN | disclosed |
| CN-117731675-A | Medical application of pentacyclic triterpene derivative, pentacyclic triterpene derivative and pharmaceutical composition containing pentacyclic triterpene derivative | 上海科技大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-117659038-A | Water-soluble triptolide prodrug compound and synthetic method and application thereof | 湖北大学 | 2024-03-08 | — | — | CN | disclosed |
| WO-2012088522-A1 | POLYMER-DES-ETHYL SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-06-28 | — | — | WO | disclosed |
| CN-102485721-A | Substituted 2,3-phthalazinone compounds and application thereof | SUZHOU KERUIGE MEDICAL TECHNOLOGY CO LTD | 2012-06-06 | — | — | CN | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-7449315-B2 | Bifunctional energy-reversible acyl-compositions | CRYOLIFE, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7429597-B2 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-09-30 | — | — | US | disclosed |
| US-20070167644-A1 | BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS | CRYOLIFE, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-7157458-B2 | Bifunctional energy-reversible acyl-compositions | CRYOLIFE, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002522-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | OSTC, FUT6, MAN2B2 | TDP1 1306/4885MEN1 2389/4885GAA 40/4885 |
| US-20070167644-A1 | BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS | ACACB, ACAT1, ACACA | TDP1 3994/4885MEN1 2547/4885GAA 1935/4885 |
| US-12291539-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | TDP1 3020/4885MEN1 721/4885GAA 885/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | TDP1 744/4885MEN1 514/4885GAA 1870/4885 |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | F11, F12, F2 | TDP1 235/4885MEN1 474/4885GAA 2024/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TDP1 3020/4885MEN1 721/4885GAA 885/4885 |
| US-20250019387-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TDP1 3020/4885MEN1 721/4885GAA 885/4885 |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | TDP1 611/4885MEN1 407/4885GAA 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.